CSNK1A1 and Alzheimer disease: Above mentioned N-(benzo[d]thiazol-2-yl)-2-phenylacetamide CK1 inhibitors are very similar in their structure to some 1-(benzo[d]thiazol-2-yl)-3-phenylureas7, which were originally prepared and tested as inhibitors of amyloid-beta binding alcohol dehydrogenase (ABAD) for treatment of AD.